Mode
Text Size
Log in / Sign up
Phase 4 N=31 Randomized Double-blind Treatment

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

Atopic Dermatitis

Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Apr 2011
Primary outcome: Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Sodium hypochlorite (bleach) baths (Drug); Mupirocin ointment (Drug); Water (Drug); Petrolatum Ointment (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Mar 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Eczema Area and Severity Index (EASI)Scores According to Location
-1.06; -0.57; -4.94; -0.88

Summary

Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.

Eligibility Criteria

Inclusion Criteria

  • 6 months to 17 years of age
  • Moderate to severe atopic dermatitis

Exclusion Criteria

  • Use of cephalexin or other antibiotic in last 6 weeks
  • Allergy to cephalosporins
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00179959). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search